|
 |
VisudyneThis page contains recent news articles, when available, and an overview of Visudyne but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.QLT Inc. (QLTI) will soon have exclusive US sales and marketing rights to Visudyne after reaching a restructured agreement with Novartis Pharma AG (NVG), ... Wall Street Journal QLT Q3 2009 Earnings Call Transcript - Oct 27, 2009 The risk of future sales of Visudyne or Elegard may be less than expected. Uncertainties relating to costs and success of R&D, commercialization of products ... Seeking Alpha (blog) QLT restructures Visudyne(R) agreement - Oct 19, 2009 QLT will continue to manufacture Visudyne and will supply the product at a pre-specified price exclusively to Novartis for ex-US distribution. ... Reuters QLT, Novartis restructure Visudyne deal; Teva launches Copaxone patent battle ... - Oct 19, 2009 Canadian eye-care company QLT said it restructured its pact with Novartis, giving it exclusive rights to sell anti-blindness treatment Visudyne in the ... FiercePharma QLT announces Toronto Stock Exchange approval of share repurchase program - Oct 28, 2009 We utilize two unique technology platforms, photodynamic therapy (used with the Visudyne product) and punctal plugs, which are currently under development ... Reuters QLT Inc. Reports Operating Results (10-Q) - Nov 6, 2009 Under the Amended PDT Agreement, effective January 1, 2010, we will, among other things, receive exclusive US rights to the Visudyne® patents to sell and ... GuruFocus.com QLT announces third quarter results for 2009 - Oct 27, 2009 Worldwide Product Sales Worldwide Visudyne(R) sales for the third quarter were $23.5 million, a decrease of 31.1% from sales in the third quarter of 2008. ... Reuters Materials Stocks Lead TSX To Four-Week High - Canadian Commentary - Oct 19, 2009 ...under which it will receive exclusive US rights to the Visudyne patents to sell and market Visudyne in the US the stock lost 2.7% on the day. ... RTT News QLT Announces Share Repurchase Program - Oct 27, 2009 We utilize two unique technology platforms, photodynamic therapy (used with the Visudyne product) and punctal plugs, which are currently under development ... Reuters NEW YORK, Oct 19 (Reuters) - Some US stocks to watch on Monday: - Oct 19, 2009 The company restructured its pact with Novartis Pharma AG, giving it exclusive rights to sell the anti-blindness treatment Visudyne in the United States. ... Forbes QLT Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new ... - Nov 13, 2009 QLT has two commercial products, Visudyne and Eligard. Visudyne utilizes photodynamic therapy (PDT), to treat the eye disease known as wet age related ... PR-inside.com (press release) AAO: Photodynamic Therapy No Help in Treating Macular Degeneration - Oct 29, 2009 Visual acuity after 12 months of verteporfin (Visudyne) plus ranibizumab (Lucentis) was statistically noninferior to ranibizumab monotherapy (P=0.0051), ... MedPage Today New Report Just Published Ophthalmological Therapeutics: A Promising and ... - Oct 23, 2009 Sales and Revenue Figures for Visudyne and US Sales Share, 2000-2006 Table 5.1. Selected Alcon IP Documents Directed at Glaucoma and Published in 2006 Table ... Live-PR.com (Pressemitteilung) Early Movers: Pump Up the Volume - Oct 19, 2009 ...it restructured an agreement with Novartis (NVS Quote) to receive exclusive US rights to sell and market the anti-blindness treatment Visudyne in the US ... TheStreet.com CA-BUSINESS Summary - Oct 19, 2009 The company, which shares revenue from Visudyne sales with global marketing partner Novartis, said it will also have rights to all end-user revenue derived ... ReportonBusiness.com Pay Attention To QLT - Oct 29, 2009 Revenues for QLT now come from a single product, Visudyne, which is marketed by drug giant Novartis (NYSE: NVS). Its second product, Eligard, ... Investopedia CA-BUSINESS Summary - Oct 19, 2009 The company, which shares revenue from Visudyne sales with global marketing partner Novartis, said it will also have rights to all end-user revenue derived ... ReportonBusiness.com CANADA STOCKS-TSX could follow commodities to higher open - Oct 19, 2009 VX: Quote, Profile, Research), giving QLT the exclusive rights to sell anti-blindness treatment Visudyne in the United States. ... Reuters India QLTé‡?整与Novartis Pharma AG之间å??è®® - Oct 19, 2009 ...(QLTI) 3.98 : QLT宣布，他们é‡?整与NovartIS Pharma AG之间å??议，将简化å?Œæ–¹å…³ç³»ï¼Œä»Ž2010å¹´1月1日起，QLT独家å?–å¾—Visudyne专利æ?ƒçš„美国拳利，将在美国销售与 ... 凤凰网 QLT Inc. Reports Operating Results (10-Q) - Aug 6, 2009 The increase was mainly due to a $4.6 million inventory write-down related to Visudyne, offset by lower cost of sales related to the drop in Visudyne sales. GuruFocus.com Mass. Eye and Ear receives $126 million after verteporfin lawsuit - Aug 6, 2009 ...from the recent resolution of a nearly decade-long lawsuit concerning the hospital's role in the development of verteporfin for injection (Visudyne). Modern Medicine AMA survey canvasses cataract cuts - Aug 28, 2009 One of the drugs, Lucentis, was said to cost about $11700 a year a patient, while the other, Visudyne, was expected to cost $5000 a year. The Australian Senior fights to save sight - Jul 10, 2009 Johanna, who lives independently with her husband Peter, 81, underwent her first treatment with Visudyne in an effort to halt the progression of the disease Langley AdvanceNews BC to approve two new drugs to treat disease that could cause ... - Apr 8, 2009 BC currently funds only one drug - Visudyne - but it hasn't proven effective for many seniors who've had to spend over $1600 per treatment every six weeks The Canadian Press Research and Markets: Analysis of AERS Data on AMD Therapeutics - Mar 31, 2009 This report provides a detailed analysis on the adverse events reported against the prescribed AMD drugs namely Lucentis, Macugen and Visudyne for the Business Wire (press release) QLT Inc.(NASDAQ:QLTI) - Eligard sales to support top-line growth ... - Apr 8, 2009 However, Visudyne continued to demonstrate weak performance during the quarter. We believe Visudyne sales will continue to be negatively impacted, Research Oracle Acucela Hires Head of Clinical Development and Regulatory Affairs - Mar 30, 2009 During the past 19 years, Dr. Boman has played a key role in successfully submitting 15 drug applications for approval, including Visudyne while at QLT. Business Wire (press release) 黄斑部病å?˜èƒ½å?¦æ²»å¥½? - Apr 10, 2009 ...è¿™ç§?光动力å¦æ²»ç–—将一ç§?特殊的光æ•?剂Visudyne注入血管，当其在眼内积累到一定é‡?时，用一ç§?特定的激光将光æ•?剂激活，激活的光æ•?剂释放大é‡?的自由基和å?•æ€?æ°§ï¼Œç ´å??细胞 医盟网健康资讯 Research, is needed now more than ever - 18 Mar 2009 ...the creation of drug-eluting stents, the design of Visudyne for preventing blindness in seniors) and makes our lives easier (the Internet tools WebCT, The Gazette (Montreal) QLT denied rehearing in MEEI claim - Feb 24, 2009 QLT estimated that the amount of damages and interest that QLT is required to pay MEEI could be about $113.2 million, based on net sales of Visudyne of Reuters QLT records profit; still 'challenges to overcome' - Feb 20, 2009 Still, with sales of the company's Visudyne antiblindness eye treatment on the wane and with its inability to find a buyer for its Eligard business, Globe and Mail Economic and Clinical Value: Key Drivers for New Product ... - Mar 2, 2009 As a result, the Visudyne product team made assumptions that were not in the end supported by economic and clinical data. Visudyne received approval from Medical Device Link (press release) Business Briefs - Feb 20, 2009 Visudyne revenue fell 12.7 per cent to $11.9 million, while product and royalty revenue related to Eligard rose 41.4 per cent to $24 million. London Free Press QLT announces completion of Phase Ia safety trial of its synthetic ... - Mar 12, 2009 QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of PR Newswire (press release) QLT rises to profit on Eligard sales - Feb 19, 2009 Quarterly revenue for Visudyne, which the company shares with global marketing partner Novartis, fell 32.7 percent to $30.6 million, while revenue from Alibaba News Channel Research Oracle roundup for 20 February 2009 - Feb 20, 2009 ...we remain concerned over QLT’s weak product pipeline, with no strong product expected over the next 2 years and weakening sales of Visudyne. Research Oracle AMD najczÄ™stszÄ… przyczynÄ… Å›lepoty osób starszych - Mar 5, 2009 Obecnie odchodzi siÄ™ od laseroterapii na rzecz terapii fotodynamicznej z werteporfinÄ… (preparat Visudyne). Polega ona na wprowadzeniu do krwiobiegu barwnika Puls Medycyny QLT says Q4 sales of Visudyne down 32.7 per cent compared with ... - Jan 12, 2009 VANCOUVER, BC - QLT Inc. (TSX:QLT) said Monday that global sales of Visudyne in the fourth quarter were down 32.7 per cent compared with a year ago. News1130, QLT Announces Appeal Court Decision on Massachusetts Eye and Ear ... - Jan 12, 2009 Unless the decision is altered on further review, based on net sales of Visudyne(R) through December 31, 2008 of approximately $2.6 billion, QLT estimates FOXBusiness Drug maker QLT Inc. values share buyback at $50 million - Jan 27, 2009 Based on net sales of Visudyne through Dec. 31 of approximately $2.6 billion, QLT estimates it will be required to pay about US$113.2 million. The Canadian Press, QLT announces preliminary results of tender offer - Jan 27, 2009 QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of PR Newswire (press release), QLT tenders for $50 million - Feb 1, 2009 The company, which pioneered the once hugely anticipated blindness cure Visudyne, has been fighting increased competition and heavy losses for years. The Province, Vancouver biotech closes US$50 million buyback in bid to raise ... - Jan 28, 2009 QLT recently reported a 34% annual decline in global sales of its signature Visudyne macular degeneration drug to US$141.9 million for the year ending Business in Vancouver, BRIEF-QLT Q4 Visudyne sales down 32.7 pct - Jan 12, 2009 The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior Forbes, US appeal court backs unfair trading decision - Jan 14, 2009 Based on net sales of Visudyne through Dec. 31 of approximately $2.6 billion, QLT estimates it will be required to pay the Massachusetts Eye and Ear Toronto Star, NovaGold reassures investors over review - Jan 22, 2009 In the original 2007 judgment, QLT was ordered to pay MEEI damages equal to 3.01 percent on past, present and future worldwide net sales of Visudyne plus Business Edge, Other News To Note - Jan 13, 2009 5798349 and certain of MEEI's research results related to QLT's Visudyne. The Court of Appeals upheld the liability and damages aspects of the 2007 judgment TMCnet BRIEF-QLT Q4 Visudyne sales down 32.7 pct - Jan 12, 2009 Interactive Investor Trading Limited, trading as "Interactive Investor", is authorised and regulated by the Financial Services Authority. Interactive Investor, QLT announces new expiration date of tender offer - Jan 15, 2009 ...photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. FOXBusiness Ranibizumab Helps Patients with Wet Macular Degeneration Function ... - Jan 16, 2009 16 -- For patients with neovascular age-related macular degeneration, ranibizumab (Lucentis) outperformed photodynamic therapy with verteporfin (Visudyne) MedPage Today, Business News - Jan 13, 2009 3.01 per cent of past, present and future worldwide sales of Visudyne - a treatment for macular degeneration - plus interest and certain legal fees. AOL Canada, Business News - Jan 12, 2009 VANCOUVER, BC - QLT Inc. (TSX:QLT) said Monday that global sales of Visudyne in the fourth quarter were down 32.7 per cent compared with a year ago. AOL Canada, QLT announces interim results of radical study evaluating Visudyne ... - Dec 16, 2008 ...(CA:QLT: news, chart, profile) today announced six-month results from an interim analysis for the Phase II RADICAL study (Reduced Fluence Visudyne MarketWatch QLT shares buck falling market on buyback - Dec 1, 2008 QLT has been selling off assets since January, when it announced a plan to focus on its macular degeneration treatment Visudyne. CNNMoney.com QLT announces commencement of tender offer - Dec 5, 2008 QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of MarketWatch QLT to repurchase up to US$ 50 million of common shares - Modified ... - Dec 1, 2008 QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of SYS-CON Media, Cerimon Pharmaceuticals Appoints James S. Shannon, MD, to Board of ... - Dec 2, 2008 ...including Diovan(R), Tekturna(R), Gleevec(R), Femara(R), Zometa(R), Reclast(R), Lucentis(R) (ex-US), Starlix(R), Visudyne(R) and Xolair(R). SYS-CON Brasil, QLT eyes share buyback as divestitures provide cash - Oct 28, 2008 Third-quarter revenue fell 25.6 percent to $10.9 million as a drop in sales of Visudyne, aimed at fighting macular degeneration, was only partly offset by Forbes, QLT announces third quarter results for 2008 - Oct 28, 2008 Also, our royalty revenue from Visudyne(R) and Eligard(R) continue to be significant to the Company and provide additional funding for our internal SYS-CON Brasil, QLT Inc - Premium Company Profile - New Research Report on ... - Nov 14, 2008 QLT has two marketed products: Visudyne for the treatment of wet age-related macular degeneration (AMD), pathologic myopia and presumed ocular Live-PR.com (Pressemitteilung), TOP MARKET NEWS - Oct 28, 2008 ...(RTTNews) - Global Visudyne sales declined 30.1% during the quarter, while worldwide sales of Eligard increased 18.3% over the third quarter of 2007. RTT News, QLT announces encouraging Phase II data from core study of Punctal ... - Oct 28, 2008 QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of SYS-CON Media, QLT Inc. (NASDAQ:QLTI) - Operating performance exceeded our ... - Oct 29, 2008 ...we remain concerned for QLT’s weak product pipeline, with no strong product expected over the next 2 years and weakening sales of Visudyne. Research Oracle, TSX may rise on oil, banks may offset - Oct 28, 2008 It also said it expected sales of Visudyne, aimed at fighting macular degeneration, for the year will be at the low end of its forecast range. Calgary Herald, Technical Trade Alert on Market Movers: INCY, QLTI, LINTA, PDGI ... - Nov 10, 2008 QLT is a global biopharmaceutical company with two commercial products, Visudyne and Eligard, which were derived from its two technology platforms, Baystreet.ca, Research Oracle roundup for 29 October 2008 - Oct 29, 2008 ...we remain concerned for QLT’s weak product pipeline, with no strong product expected over the next 2 years and weakening sales of Visudyne. Research Oracle, |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
